Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

The Naira further appreciated in the official market on Friday, trading at N1,474.78 to the Dollar. Data from the FMDQ Securities Exchange official forex trading platform revealed that the Naira ...

Register now to receive the latest news, purchase tickets and get exclusive access to Aston Villa content as well as a host of other benefits ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

ATH434 recently announced positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA. A second Phase 2 open-label 2 Biomarker ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 from the previous $1,230. Despite the reduction, the firm maintained a Buy ...

Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.65% as of 30 ...